BIODESIX INC Stock Price, News & Analysis

Biodesix (Nasdaq: BDSX) announced its CEO, Scott Hutton, will present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 12:30 PM ET. The presentation will be available for live streaming and replay on the company's website. Biodesix focuses on innovative diagnostic solutions for lung diseases, offering non-invasive tests and leveraging AI technology. The company has developed tests for COVID-19, including SARS-CoV-2 ddPCR™, and its lung cancer strategies help expedite treatment decisions. More details can be found at biodesix.com.

Biodesix (Nasdaq: BDSX) will release its second-quarter financial results on August 10, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss these results and provide a business update. The company is recognized for developing diagnostic tests for lung diseases, including recent contributions to COVID-19 diagnostics. Biodesix's innovative tests aid in critical treatment decisions and cancer risk assessments, leveraging advancements in artificial intelligence.

Biodesix (Nasdaq: BDSX) announced a webinar in collaboration with Seer to discuss proteomics trends in biomarker discovery on June 22, 2021. The event features experts discussing the Seer Proteograph™ Product Suite, which enhances plasma protein analysis to support Biodesix's diagnostic tests. As a leader in lung disease diagnostics, Biodesix combines proteomic and genomic insights through AI. They have launched several COVID-19 tests and provide rapid lung cancer treatment decision support through their innovative testing strategies.

Biodesix, Inc. (BDSX) has announced the commercial launch of its SARS CoV-2 Neutralization Antibody Test (cPass™), authorized by the FDA for emergency use. This test detects neutralizing antibodies against SARS-CoV-2's receptor binding domain, indicating immunity from prior infection or vaccination. It is particularly significant for immunocompromised individuals, providing crucial data for healthcare providers for better management. The launch of the cPass test emphasizes Biodesix's commitment to addressing lung disease diagnostics and support for patient treatment decisions.

Biodesix (BDSX) has announced a strategic partnership with Datavant to enhance lung cancer diagnostics. This collaboration enables Biodesix to anonymize its lung cancer biobank, consisting of 150,000 samples, and link it to real-world data sets securely. The partnership aims to improve clinical decision-making and inform biopharma companies throughout the product development cycle. Biodesix's ongoing INSIGHT study will also contribute treatment decisions and outcomes data, providing a comprehensive view of patient health while ensuring patient privacy.

Biodesix (BDSX) and the Addario Lung Cancer Medical Institute announced the enrollment of the first patient in the BEACON-Lung study, aimed at evaluating biomarkers for predicting survival in advanced-stage non-small cell lung cancer (NSCLC) patients. This study will utilize Biodesix's Primary Immune Response (PIR) test to identify patients who may benefit from PD-1/PD-L1 therapy. Targeting 390 patients across nearly 10 sites, the study will enhance understanding of treatment options and improve survival rates for NSCLC patients.

Biodesix (Nasdaq: BDSX) announced CEO Scott Hutton will present at the William Blair 41st Annual Growth Stock Conference virtually on June 2, 2021, at 2:00 PM CT. The presentation will be available for live streaming and later replay on the company's website under the Investors section. Biodesix specializes in data-driven diagnostic solutions for lung diseases, offering six non-invasive tests and innovative strategies for lung cancer and COVID-19 diagnostics. For more details, visit biodesix.com.

Biodesix reported strong performance for Q1 2021, with total revenue of $28.9 million, a 466% increase YoY. COVID-19 testing contributed $23.2 million, up 8% Q/Q, while lung diagnostics revenue grew by 10% YoY. The company secured a $30 million term loan, enhancing liquidity and aiding future expansion. Net loss improved by 28% YoY to $7 million. Additionally, Biodesix introduced new tests and patents, enhancing its lung diagnostics portfolio and COVID-19 testing capabilities.

Biodesix (BDSX) is set to enhance its diagnostic portfolio with a new blood-based 52-gene next-generation sequencing (NGS) test for non-small cell lung cancer (NSCLC). This test, based on recent research, boasts a rapid turnaround time of just 72 hours, significantly faster than the existing options which take 7-14 days. Currently, the test is utilized in biopharma research and will augment Biodesix's GeneStrat® ddPCR and VeriStrat® tests, enabling comprehensive genomic data for treatment decisions. The company anticipates launching this innovative test in the first half of 2022.